479 related articles for article (PubMed ID: 16258815)
1. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases.
Matsuzaki S; Rashel M; Uchiyama J; Sakurai S; Ujihara T; Kuroda M; Ikeuchi M; Tani T; Fujieda M; Wakiguchi H; Imai S
J Infect Chemother; 2005 Oct; 11(5):211-9. PubMed ID: 16258815
[TBL] [Abstract][Full Text] [Related]
2. Phage therapy: facts and fiction.
Skurnik M; Strauch E
Int J Med Microbiol; 2006 Feb; 296(1):5-14. PubMed ID: 16423684
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Bacteriophage Preparations on Intracellular Killing of Bacteria by Phagocytes.
Jończyk-Matysiak E; Łusiak-Szelachowska M; Kłak M; Bubak B; Międzybrodzki R; Weber-Dąbrowska B; Żaczek M; Fortuna W; Rogóż P; Letkiewicz S; Szufnarowski K; Górski A
J Immunol Res; 2015; 2015():482863. PubMed ID: 26783541
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic potential of bacteriophages targeting gram-negative bacteria using Galleria mellonella infection model.
Manohar P; Nachimuthu R; Lopes BS
BMC Microbiol; 2018 Aug; 18(1):97. PubMed ID: 30170558
[TBL] [Abstract][Full Text] [Related]
5. Bacteriophages and bacteriophage-derived endolysins as potential therapeutics to combat Gram-positive spore forming bacteria.
Nakonieczna A; Cooper CJ; Gryko R
J Appl Microbiol; 2015 Sep; 119(3):620-31. PubMed ID: 26109320
[TBL] [Abstract][Full Text] [Related]
6. PlyKp104, a Novel Phage Lysin for the Treatment of Klebsiella pneumoniae, Pseudomonas aeruginosa, and Other Gram-Negative ESKAPE Pathogens.
Euler CW; Raz A; Hernandez A; Serrano A; Xu S; Andersson M; Zou G; Zhang Y; Fischetti VA; Li J
Antimicrob Agents Chemother; 2023 May; 67(5):e0151922. PubMed ID: 37098944
[TBL] [Abstract][Full Text] [Related]
7. LysSAP26, a New Recombinant Phage Endolysin with a Broad Spectrum Antibacterial Activity.
Kim S; Jin JS; Choi YJ; Kim J
Viruses; 2020 Nov; 12(11):. PubMed ID: 33238548
[TBL] [Abstract][Full Text] [Related]
8. Phage Therapy Is Effective in a Mouse Model of Bacterial Equine Keratitis.
Furusawa T; Iwano H; Hiyashimizu Y; Matsubara K; Higuchi H; Nagahata H; Niwa H; Katayama Y; Kinoshita Y; Hagiwara K; Iwasaki T; Tanji Y; Yokota H; Tamura Y
Appl Environ Microbiol; 2016 Sep; 82(17):5332-9. PubMed ID: 27342558
[TBL] [Abstract][Full Text] [Related]
9. Preventing biofilms of clinically relevant organisms using bacteriophage.
Donlan RM
Trends Microbiol; 2009 Feb; 17(2):66-72. PubMed ID: 19162482
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial activity of Acinetobacter baumannii phage ϕAB2 endolysin (LysAB2) against both gram-positive and gram-negative bacteria.
Lai MJ; Lin NT; Hu A; Soo PC; Chen LK; Chen LH; Chang KC
Appl Microbiol Biotechnol; 2011 Apr; 90(2):529-39. PubMed ID: 21264466
[TBL] [Abstract][Full Text] [Related]
11. Delivering phage therapy per os: benefits and barriers.
Zelasko S; Gorski A; Dabrowska K
Expert Rev Anti Infect Ther; 2017 Feb; 15(2):167-179. PubMed ID: 27885865
[TBL] [Abstract][Full Text] [Related]
12. The antibacterial activity of E. coli bacteriophage lysin lysep3 is enhanced by fusing the Bacillus amyloliquefaciens bacteriophage endolysin binding domain D8 to the C-terminal region.
Wang S; Gu J; Lv M; Guo Z; Yan G; Yu L; Du C; Feng X; Han W; Sun C; Lei L
J Microbiol; 2017 May; 55(5):403-408. PubMed ID: 28124780
[TBL] [Abstract][Full Text] [Related]
13. A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans.
El Haddad L; Harb CP; Gebara MA; Stibich MA; Chemaly RF
Clin Infect Dis; 2019 Jun; 69(1):167-178. PubMed ID: 30395179
[TBL] [Abstract][Full Text] [Related]
14. A genetic screen to identify bacteriophage lysins.
Schuch R; Fischetti VA; Nelson DC
Methods Mol Biol; 2009; 502():307-19. PubMed ID: 19082564
[TBL] [Abstract][Full Text] [Related]
15. Beyond the CRISPR-Cas safeguard: PICI-encoded innate immune systems protect bacteria from bacteriophage predation.
Fillol-Salom A; Miguel-Romero L; Marina A; Chen J; Penadés JR
Curr Opin Microbiol; 2020 Aug; 56():52-58. PubMed ID: 32653777
[TBL] [Abstract][Full Text] [Related]
16. Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens.
Burrowes B; Harper DR; Anderson J; McConville M; Enright MC
Expert Rev Anti Infect Ther; 2011 Sep; 9(9):775-85. PubMed ID: 21905786
[TBL] [Abstract][Full Text] [Related]
17. The endolysin of the Acinetobacter baumannii phage vB_AbaP_D2 shows broad antibacterial activity.
Yuan Y; Li X; Wang L; Li G; Cong C; Li R; Cui H; Murtaza B; Xu Y
Microb Biotechnol; 2021 Mar; 14(2):403-418. PubMed ID: 32519416
[TBL] [Abstract][Full Text] [Related]
18. Molecular Basis of Bacterial Host Interactions by Gram-Positive Targeting Bacteriophages.
Dunne M; Hupfeld M; Klumpp J; Loessner MJ
Viruses; 2018 Jul; 10(8):. PubMed ID: 30060549
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
Vega S; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of Gram-negative and Gram-positive microorganisms against Helicobacter pylori clinical isolates.
López-Brea M; Alarcón T; Domingo D; Díaz-Regañón J
J Antimicrob Chemother; 2008 Jan; 61(1):139-42. PubMed ID: 17965421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
